Atossa Therapeutics, Inc.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, in the United States. According to its official website, the company is focused on addressing significant unmet needs in hormone-driven oncology and rare diseases, describing itself as a "dual-focused innovator" committed to advancing therapies and improving patient care for people suffering from hormone-driven conditions. Its clinical platform is centered on the next-generation selective estrogen receptor modulator/degrader (SERM/D) known as (Z)-endoxifen. The company's stated mission is to translate differentiated science into therapies that can improve outcomes across the course of disease, from risk reduction and earlier intervention to the treatment of established disease. Atossa began with a focus on breast health and has evolved into a clinical-stage company developing (Z)-endoxifen across breast cancer and selected rare diseases where estrogen-related biology may be therapeutically relevant. Building on its established foundation in breast cancer, the company is leveraging the pro-estrogenic or anti-estrogenic attributes of its SERM/D compound to expand clinical research and development beyond breast cancer and into rare diseases such as McCune-Albright Syndrome and Duchenne Muscular Dystrophy. The company takes its name from Princess Atossa of ancient Persia, whose story is often cited as one of the earliest recorded accounts of treatment for breast cancer more than two millennia ago. Atossa frames this heritage as reflecting a long-standing medical goal: to intervene against disease in ways that preserve health and improve outcomes. Atossa Therapeutics is led by a management team that includes Steven C. Quay, M.D., Ph.D., as Chairman of the Board and Chief Executive Officer; Mark Daniel as Chief Financial Officer; Delly Behen as Senior Vice President, Business Operations; and Janet R. Rea, MSPH, as Senior Vice President, Research & Development. Its board of directors includes Steven C. Quay, Shu-Chih Chen, Ph.D., Tessa Cigler, M.D., M.P.H., Jonathan F. Finn, Stephen J. Galli, MD, H. Lawrence Remmel, Esq., and Richard I. Steinhart. Culturally, the company describes itself as a focused, collaborative team working across clinical development, regulatory affairs, science, operations, and finance, with a remote-friendly work environment. It emphasizes rigorous thinking, open discussion, accountability, and respect for different perspectives, and says it works across functions to advance clear development milestones while keeping patients, partners, and shareholders in view. As a clinical-stage company, Atossa's near-term value and progress are tied to the advancement of its (Z)-endoxifen clinical programs rather than to marketed commercial products.

Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, in the United States. The company takes its name from Princess Atossa of ancient Persia, whose story is often cited as one of the earliest recorded accounts of treatment for breast cancer more than two millennia ago. According to the company's own account, Atossa began with a focus on breast health and has since evolved into a clinical-stage company developing (Z)-endoxifen across breast cancer and selected rare diseases where estrogen-related biology may be therapeutically relevant. Over the course of that evolution, the company's clinical platform has come to center on the next-generation selective estrogen receptor modulator/degrader (SERM/D) known as (Z)-endoxifen. Atossa describes itself as a dual-focused innovator, committed to advancing therapies and improving patient care for those suffering from hormone-driven conditions. Its stated mission is to translate differentiated science into therapies that can improve outcomes across the course of disease, from risk reduction and earlier intervention to the treatment of established disease. Building on its established foundation in breast cancer, Atossa is leveraging the pro-estrogenic or anti-estrogenic attributes of its SERM/D compound to expand clinical research and development beyond breast cancer and into rare diseases such as McCune-Albright Syndrome and Duchenne Muscular Dystrophy. Through this approach, the company aims to apply well-characterized mechanisms across ER+ breast cancer and rare diseases to improve patient outcomes and broaden therapeutic options for patients. The company is led by a management team that includes Steven C. Quay, M.D., Ph.D., as Chairman of the Board and Chief Executive Officer; Mark Daniel as Chief Financial Officer; Delly Behen as Senior Vice President, Business Operations; and Janet R. Rea, MSPH, as Senior Vice President, Research & Development. Its board of directors includes Steven C. Quay, Shu-Chih Chen, Ph.D., Tessa Cigler, M.D., M.P.H., Jonathan F. Finn, Stephen J. Galli, MD, H. Lawrence Remmel, Esq., and Richard I. Steinhart. Atossa describes its culture as focused and collaborative, with teams working across clinical development, regulatory affairs, science, operations, and finance. The company says it values rigorous thinking, open discussion, accountability, and respect for different perspectives, and that its teams work across functions to advance clear development milestones while keeping patients, partners, and shareholders in view. It also describes a remote-friendly work environment with competitive benefits. As a clinical-stage company, Atossa's progress is measured primarily through the advancement of its (Z)-endoxifen clinical programs rather than through marketed commercial products.

Clinical-stage biopharmaceutical company focused on hormone-driven oncology and rare diseases, centered on its next-generation SERM/D (Z)-endoxifen.

• (Z)-endoxifen

  Next-generation selective estrogen receptor modulator/degrader (SERM/D) that forms the center of Atossa's clinical platform, being developed across ER+ breast cancer and selected rare diseases.

1. 1Atossa Therapeutics, Inc - Advancing Hormone Driven Careatossatherapeutics.com
2. 2Who We Are - Atossa Therapeutics, Incatossatherapeutics.com
3. 3About Us - Atossa Therapeutics, Incatossatherapeutics.com
4. 4Our Culture - Atossa Therapeutics, Incatossatherapeutics.com
5. 5Atossa Therapeutics (United States) - Wikidatawikidata.org